A5007719765- Smoking Behavior and Cessation
- Cannabis and Cannabinoid Research
- Nicotinic Acetylcholine Receptors Study
- Schizophrenia research and treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Substance Abuse Treatment and Outcomes
- Neurotransmitter Receptor Influence on Behavior
- Child and Adolescent Psychosocial and Emotional Development
- Behavioral Health and Interventions
- Bipolar Disorder and Treatment
- Diet and metabolism studies
- Obesity, Physical Activity, Diet
- Treatment of Major Depression
- Prenatal Substance Exposure Effects
- Functional Brain Connectivity Studies
- Mental Health Research Topics
- Neuroscience and Neuropharmacology Research
- Neural and Behavioral Psychology Studies
- Homelessness and Social Issues
- Olfactory and Sensory Function Studies
- Mental Health Treatment and Access
- Tryptophan and brain disorders
- Diabetes Management and Education
- Sleep and Wakefulness Research
- Diabetes Management and Research
Massachusetts General Hospital
2016-2025
Harvard University
2015-2024
Boston University
2003-2024
Lemuel Shattuck Hospital
2008-2023
McGovern Institute for Brain Research
2023
Dartmouth College
2012-2022
Boston Medical Center
2022
University College London
2020
Pfizer (United States)
2020
Fred Hutch Cancer Center
2020
It is estimated that more than half of those with serious mental illness smoke tobacco regularly. Standard courses pharmacotherapeutic cessation aids improve short-term abstinence, but most who attain abstinence relapse rapidly after discontinuation pharmacotherapy.To determine whether smokers diagnosed schizophrenia and bipolar disease have higher rates prolonged maintenance pharmacotherapy standard treatment.Randomized, double-blind, placebo-controlled, parallel-group, relapse-prevention...
Section:ChooseTop of pageAbstract <<ContentsSummary Recommendation...IntroductionMethodsQuestions and Recommendat...DiscussionPatient PerspectiveReferencesCITING ARTICLES
<h3>Background</h3> While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated certain atypical antipsychotic agents, it remains unclear whether agents are directly affecting glucose metabolism or simply known risk factors for diabetes. <h3>Objective</h3> To study 2 drugs most clearly implicated (clozapine and olanzapine) risperidone using a frequently sampled intravenous tolerance test. <h3>Design</h3> A cross-sectional design stable,...
Article Abstract Objective: The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change cardiovascular risk factors following clozapine initiation and mortality estimates from disease. Method: Data were collected medical records January 1992 December 2003 included age, gender, race, diagnosis, family history diabetes, age at for patients with schizophrenia or schizoaffective disorder (DSM-IV criteria). Clozapine dosage laboratory results recorded...
The objective of this study was to examine the efficacy bupropion for smoking cessation in patients with schizophrenia. Adults schizophrenia who smoked more than 10 cigarettes per day and wished try quit were recruited from community mental health centers, enrolled a 12-week group cognitive behavioral therapy intervention, randomly assigned receive either sustained-release 300 mg/d or identical placebo. Fifty-three adults, 25 on 28 placebo, randomized, completed at least 1 postbaseline...
The purpose of this study was to investigate the effect adding sustained-release (SR) bupropion cognitive behavioral therapy (CBT) on smoking behavior and stability psychiatric symptoms in patients with schizophrenia. We conducted a 3-month, double-blind, placebo-controlled trial SR, 150 mg/day, added concurrent CBT program 3-month follow-up 19 stable outpatients schizophrenia who wanted quit smoking. Eighteen subjects completed trial. Bupropion treatment associated significantly greater...
The objective of this study was to examine whether there is a benefit adding bupropion SR high-dose combination nicotine replacement therapy (NRT) and weekly group cognitive behavioral (CBT) for smoking reduction or cessation in schizophrenia. Fifty-one adult smokers with schizophrenia were randomly assigned 12-week trial 300 mg/d placebo added transdermal patch, polacrilex gum, CBT. treatment goal cessation. primary outcome measure biochemically confirmed 7-day point-prevalence 50% 100% at...
Abstract Animal findings have highlighted the modulatory role of phasic dopamine (DA) signaling in incentive learning, particularly acquisition reward‐related behavior. In humans, these processes remain largely unknown. a recent study, we demonstrated that single low dose D2/D3 agonist (pramipexole)—assumed to activate DA autoreceptors and thus reduce bursts—impaired reward learning healthy subjects performing probabilistic task. The purpose this study was extend behavioral using...
Neural substrates underlying the human-pet relationship are largely unknown. We examined fMRI brain activation patterns as mothers viewed images of their own child and dog an unfamiliar dog. There was a common network regions involved in emotion, reward, affiliation, visual processing social cognition when both Viewing resulted activity midbrain (ventral tegmental area/substantia nigra reward/affiliation), while more posterior cortical pattern involving fusiform gyrus (visual faces...
Neuropsychiatric safety and relative efficacy of varenicline, bupropion, transdermal nicotine patch (NRT) in those with psychiatric disorders are interest.
<h3>Importance</h3> Persons with serious mental illness have a cardiovascular disease mortality rate more than twice that of the overall population. Meaningful risk reduction requires targeted efforts in this population, who often psychiatric symptoms and cognitive impairment. <h3>Objective</h3> To determine effectiveness an 18-month multifaceted intervention incorporating behavioral counseling, care coordination, management for adults illness. <h3>Design, Setting, Participants</h3> This...